Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Drug Research
Drug Delivery
Return to: PBR Home | Drug Research | Drug Delivery | News
Search Refinements

Drug Delivery News

View news from other Pharmaceutical sectors:
106-120 of 2284 results
Caladrius Biosciences secures FDA orphan drug designation for CLBS03 to treat type 1 diabetes
The US Food and Drug Administration (FDA) has granted orphan-drug designation to Caladrius Biosciences' CLBS03 to treat type 1 diabetes mellitus with residual beta cell function.
Drug Research > Drug Delivery > News
NLS Pharma submits IND to FDA for Mazindol to treat ADHD
NLS Pharma Group has submitted an Investigational New Drug Application (IND) with the U.S. Food and Drug Administration (FDA) to initiate a Phase IIb clinical trial with its lead compound Mazindol.
Drug Research > Drug Delivery > News
Crown Bioscience establishes EGFR-mutated non-small cell lung cancer models
Crown Bioscience has recently published on the establishment and characterization of a set of NSLCL patient-derived xenograft (PDX) models that harbor non-canonical EGFR mutations.
Drug Research > Drug Delivery > News
ANI Pharmaceuticals launches 50mg and 150mg Fenofibrate Capsules in ANI label
ANI Pharmaceuticals announced the commercial launch of 50mg and 150mg fenofibrate capsules USP (the authorized generic of Lipofen) in the ANI label.
Drug Research > Drug Delivery > News
WAVE Life Sciences to advance next-generation nucleic acid therapies for Duchenne Muscular Dystrophy
WAVE Life Sciences has reaffirmed its commitment to advance next-generation nucleic acid therapies to address the significant unmet need of patients diagnosed with Duchenne Muscular Dystrophy (DMD).
Drug Research > Drug Delivery > News
TOLMAR wins FDA approval for ELIGARD to treat advanced prostate cancer
TOLMAR Pharmaceuticals has secured from FDA for a label update for ELIGARD, indicated for the palliative treatment of advanced prostate cancer.
Drug Research > Drug Delivery > News
Valeant Pharmaceuticals forms committee to oversee pricing of drugs
Valeant Pharmaceuticals International has formed a new Patient Access and Pricing Committee that will be responsible for the pricing of the company's drugs.
Drug Research > Drug Delivery > News
Mylan launches generic version of Apresoline injection in US
Mylan announced the US launch of Hydralazine Hydrochloride Injection USP, 20 mg/mL, which is a generic version of Novartis' Apresoline Injection, 20 mg/mL.
Drug Research > Drug Delivery > News
Concert Pharmaceuticals unveils CTP-543 to treat alopecia areata
Concert Pharmaceuticals has announced its next product candidate, CTP-543, for the treatment of alopecia areata.
Drug Research > Drug Delivery > News
Veristat acquires UK-based CRO, Spero Oncology
Veristat, a full service Clinical Research Organization (CRO), is expanding its clinical research offerings into Europe through the acquisition of UK-based CRO, Spero Oncology.
Drug Research > Drug Delivery > News
Heritage Pharmaceuticals issues product safety warning counterfeit drug product BiCNU
Heritage Pharmaceuticals announced that it recently became aware of the existence of a counterfeit drug product labeled as BiCNU (Carmustine for Injection) 100mg that has been sold and distributed outside of the US.
Drug Research > Drug Delivery > News
Ocular completes end-of-phase 2 review with FDA for OTX-TP for glaucoma and ocular hypertension
Ocular Therapeutix has completed its End-of-Phase 2 review with the US Food and Drug Administration (FDA) for its OTX-TP (sustained release travoprost) product candidate for the treatment of glaucoma and ocular hypertension.
Drug Research > Drug Delivery > News
Chinese Patent Office plans to grant patent relating to Immunicum's cancer immune primer INTUVAX
The Chinese Patent Office (SIPO) intends to grant a patent relating to Immunicum's cancer immune primer, INTUVAX.
Drug Research > Drug Delivery > News
Galapagos reports 20-week results from FITZROY study with JAK1 inhibitor filgotinib in Crohn's disease
Galapagos reported 20-week results from its FITZROY study with the investigational, selective JAK1 inhibitor filgotinib in Crohn's disease.
Drug Research > Drug Delivery > News
Tris Pharma launches DYANAVEL XR oral suspension, CII to treat Children with ADHD
Tris Pharma has launched DYANAVEL XR (amphetamine), CII, the first and only extended-release liquid amphetamine for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in children aged 6 years and older.
Drug Research > Drug Delivery > News
106-120 of 2284 results